{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:56:47Z","timestamp":1762865807674,"version":"3.44.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2011]]},"DOI":"10.1016\/j.cellimm.2011.04.005","type":"journal-article","created":{"date-parts":[[2011,4,25]],"date-time":"2011-04-25T00:49:52Z","timestamp":1303692592000},"page":"62-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11"],"prefix":"10.1016","volume":"270","author":[{"given":"Mark","family":"Matijevic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Lynne","family":"Hedley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G.","family":"Urban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman M.","family":"Chicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christa","family":"Lajoie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Luby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2011.04.005_b0005","first-page":"1192","article-title":"Papillomavirus vaccines","volume":"3","author":"Duggan-Keen","year":"1989","journal-title":"Front. Biosci."},{"issue":"2","key":"10.1016\/j.cellimm.2011.04.005_b0010","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00003081-200006000-00016","article-title":"Human papillomavirus infection and cervical carcinoma","volume":"43","author":"Kaufman","year":"2000","journal-title":"Clin. Obstet. Gynecol."},{"key":"10.1016\/j.cellimm.2011.04.005_b0015","first-page":"5019","article-title":"Role of human papillomaviruses in human cancer","volume":"51","author":"Howley","year":"1991","journal-title":"Cancer Res."},{"issue":"Suppl. 2","key":"10.1016\/j.cellimm.2011.04.005_b0020","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ygyno.2008.02.003","article-title":"Immunobiology of HPV and HPV vaccines","volume":"109","author":"Stanley","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.cellimm.2011.04.005_b0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ogc.2008.09.006","article-title":"Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer","volume":"35","author":"Wheeler","year":"2008","journal-title":"Obstet. Gynecol. Clin. North Am."},{"issue":"12","key":"10.1016\/j.cellimm.2011.04.005_b0030","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1007\/s12094-008-0293-7","article-title":"Human papillomavirus vaccine and cervical cancer prevention","volume":"10","author":"Oaknin","year":"2008","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.cellimm.2011.04.005_b0035","first-page":"83","article-title":"Cold-knife conization versus the loop electrosurgical excision procedure for treatment of cervical dysplasia","volume":"29","author":"Bozanovic","year":"2008","journal-title":"Eur. J. Gynaecol. Oncol."},{"issue":"1\u20132","key":"10.1016\/j.cellimm.2011.04.005_b0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1386-6532(00)00128-1","article-title":"National HPV immunity and vaccination strategies","volume":"19","author":"Stern","year":"2000","journal-title":"J. Clin. Virol."},{"issue":"2","key":"10.1016\/j.cellimm.2011.04.005_b0045","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/rmv.488","article-title":"Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity","volume":"16","author":"Hebner","year":"2006","journal-title":"Rev. Med. Virol."},{"issue":"4","key":"10.1016\/j.cellimm.2011.04.005_b0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/pgm.2008.11.1928","article-title":"HPV and cervical cancer: updates on an established relationship","volume":"120","author":"Subramanya","year":"2008","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.cellimm.2011.04.005_b0055","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0092-8674(93)90384-3","article-title":"The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53","volume":"75","author":"Scheffner","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.cellimm.2011.04.005_b0060","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1126\/science.2537532","article-title":"The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product","volume":"243","author":"Dyson","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2011.04.005_b0065","first-page":"598","article-title":"Management of anogenital warts (condylomata acuminate)","volume":"11","author":"Von Krough","year":"2001","journal-title":"Eur. J. Dermatol."},{"issue":"2","key":"10.1016\/j.cellimm.2011.04.005_b0070","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1590\/S0100-879X1999000200005","article-title":"Poly-dl-lactide-co-glycolide microspheres as a controlled release antigen delivery system","volume":"32","author":"Lima","year":"1999","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"6","key":"10.1016\/j.cellimm.2011.04.005_b0075","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1517\/14712598.3.6.903","article-title":"Formulations containing poly (lactide-co-glycolide) and plasmid DNA expression vectors","volume":"3","author":"Hedley","year":"2003","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.cellimm.2011.04.005_b0080","first-page":"265","article-title":"Microparticle delivery of plasmid DNA to mammalian cells","volume":"245","author":"Hedley","year":"2003","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.cellimm.2011.04.005_b0085","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.0105-2896.2004.00153.x","article-title":"Microparticles for the delivery of DNA vaccines","volume":"199","author":"O\u2019Hagan","year":"2004","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cellimm.2011.04.005_b0090","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0928-0987(01)00218-4","article-title":"In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres","volume":"15","author":"Prior","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.cellimm.2011.04.005_b0095","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.AOG.0000110246.93627.17","article-title":"Amolimogene for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial","volume":"103","author":"Garcia","year":"2004","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.cellimm.2011.04.005_b0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0022-1759(97)00184-1","article-title":"Evaluation of the IFN-\u03b3 ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood","volume":"210","author":"Schmittel","year":"1997","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.cellimm.2011.04.005_b0105","first-page":"1127","article-title":"Assays for monitoring cellular immune responses to active immunotherapy of cancer","volume":"7","author":"Clay","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2011.04.005_b0110","first-page":"316","article-title":"Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay","volume":"4","author":"Pass","year":"1998","journal-title":"Cancer J. Sci. Am."},{"key":"10.1016\/j.cellimm.2011.04.005_b0115","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/088922202760019301","article-title":"Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines","volume":"18","author":"Mwau","year":"2002","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.cellimm.2011.04.005_b0120","first-page":"237","article-title":"Use of Interferon-\u03b3 ELISPOT in Monitoring Immune Responses in Humans","volume":"vol. 302","author":"Matijevic","year":"2005"},{"issue":"8","key":"10.1016\/j.cellimm.2011.04.005_b0125","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1086\/382956","article-title":"Dynamics of human papillomavirus infection between biopsy and excision of cervical intraepithelial neoplasia: results from the ZYC101a protocol","volume":"189","author":"Crum","year":"2004","journal-title":"J. Infect. Dis."},{"issue":"8691","key":"10.1016\/j.cellimm.2011.04.005_b0130","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/0140-6736(90)90855-Y","article-title":"Looking for human papillomavirus type 16 by PCR","volume":"335","author":"Manos","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.cellimm.2011.04.005_b0135","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/384134a0","article-title":"Structure of the complex between human T-cell receptor, viral peptide and HLA-A2","volume":"384","author":"Garboczi","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2011.04.005_b0140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0022-1759(01)00535-X","article-title":"A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays","volume":"260 1-2","author":"Currier","year":"2002","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.cellimm.2011.04.005_b0145","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1084\/jem.174.2.489","article-title":"Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted, cell mediated lysis","volume":"174","author":"Anderson","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2011.04.005_b0150","unstructured":"M.L. Hedley, R.G. Urban, R.M. Chicz, US 2005\/0100928 A1, 2005."},{"key":"10.1016\/j.cellimm.2011.04.005_b0155","first-page":"1028","article-title":"Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101","volume":"8","author":"Klencke","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2011.04.005_b0160","first-page":"3406","article-title":"A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive","volume":"6","author":"Muderspach","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.cellimm.2011.04.005_b0165","first-page":"4855","article-title":"Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia garde III","volume":"57","author":"Nimako","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2011.04.005_b0170","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/ijc.22894","article-title":"CD4+CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia","volume":"121","author":"Molling","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.cellimm.2011.04.005_b0175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-0897.2008.00590.x","article-title":"Regulatory T cells in a spectrum of HPV-induced cervical lesions: cervicitis, cervical intraepithelial neoplasia and squamous cell carcinoma","volume":"60","author":"Adurthi","year":"2008","journal-title":"Am. J. Rep. Imm."},{"issue":"2","key":"10.1016\/j.cellimm.2011.04.005_b0180","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/157489108784746623","article-title":"Strategies for effective naked-DNA vaccination against infectious diseases","volume":"3","author":"Chiarella","year":"2008","journal-title":"Recent Patents Anti-Infect. Drug Disc."},{"key":"10.1016\/j.cellimm.2011.04.005_b0185","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.0105-2896.2004.00151.x","article-title":"DNA vaccines against human immunodeficiency virus type 1","volume":"199","author":"Estcourt","year":"2004","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cellimm.2011.04.005_b0190","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc2326","article-title":"DNA vaccines: precision tools for activating effective immunity against cancer","volume":"8","author":"Rice","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.cellimm.2011.04.005_b0195","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1128\/JVI.02694-07","article-title":"Cross-recognition of avian H5N1 influenza virus by human cytotoxic T lymphocyte populations directed to human influenza A virus","volume":"82","author":"Kreijtz","year":"2008","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.cellimm.2011.04.005_b0200","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1128\/JVI.77.9.5464-5474.2003","article-title":"Human papillomavirus type 16E7 peptide-directed CD8+ T Cells from patients with cervical cancer are cross reactive with the coronavirus NS2 protein","volume":"77","author":"Nilges","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.cellimm.2011.04.005_b0205","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1002\/ijc.21643","article-title":"Definition of an HPV 18\/45 cross-reactive human T-cell epitope after DNA immunization of HLA-A2\/KB transgenic mice","volume":"118","author":"McCarthy","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"15","key":"10.1016\/j.cellimm.2011.04.005_b0210","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.1128\/JVI.76.15.7418-7429.2002","article-title":"Analysis of CD4+ T-Cell responses to human papillomavirus (HPV) Type 11 L1 in healthy adults reveal a high degree of responsiveness and cross-reactivity with other HPV types","volume":"76","author":"Williams","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.cellimm.2011.04.005_b0215","first-page":"113","article-title":"The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy","author":"Elben","year":"2002","journal-title":"Adv. Cancer Res."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000887491100092X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000887491100092X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T22:46:14Z","timestamp":1757803574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000887491100092X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"alternative-id":["S000887491100092X"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2011.04.005","relation":{},"ISSN":["0008-8749"],"issn-type":[{"type":"print","value":"0008-8749"}],"subject":[],"published":{"date-parts":[[2011]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2011.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}